Imunon (IMNN) Registration filing summary

Use of proceeds and capital allocation

• Net proceeds designated for general corporate, capital expenditure and working capital purposes; use restricted from debt repayment except ordinary-course trade payables, stock redemptions, or FCPA/OFAC violations.

Risk factors and disclosures

• Units include warrants that may result in substantial share issuance; beneficial ownership limits generally cap exercise at 4.99% or 9.99%, with higher purchase limits available to certain existing investors.

• Further equity issuance is restricted for 45 days if gross proceeds are below $10 million or 90 days if at least $10 million; variable-rate transactions are restricted for 180 days, with an ATM exception after 60 days and a Streeterville carveout.

• Warrant exercise may depend on stockholder approval under trading-market rules; if required, approval must be pursued at a meeting within 90 days after closing, with later meetings every 90 days if needed.

• Purchasers may trade or hedge after public announcement, including short sales; warrant terms provide cashless exercise when registration is unavailable and potential remedies for delayed share delivery.

Management team and governance

• Stacy R. Lindborg is President, CEO and director; Josh Blacher is CFO; Michael H. Tardugno is Executive Chairman; signatories also include directors Frederick J. Fritz, James E. Dentzer, Donald Braun and Christine Pellizzari.

• Board representations state that at least a majority of directors qualify as independent under trading-market rules and that board composition meets applicable Sarbanes-Oxley requirements.